Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Composite score on the Brief Assessment of Cognition in Schizophrenia
研究概览
简要总结
Relationships between altered prefrontal cortical dopamine, norepinephrine and some cognitive impairments of schizophrenia supports and approach for pharmacological remediation of cognitive symptoms through manipulations of prefrontal cortical dopamine and norepinephrine. Atomoxetine, a selective norepinephrine re-uptake inhibitor, produces a widespread increase in brain norepinephrine and a secondary and selective increase in prefrontal dopamine. Given this, we are evaluating atomoxetine's cognitive effects in a pilot placebo controlled trial in patients with schizophrenia. Moreover, an fMRI investigation was undertaken to assess the neural mechanisms underlying the cognitive effects of atomoxetine.
详细描述
Participants carrying a diagnosis of schizophrenia and receiving treatment with one of the following antipsychotic medications are eleigible for participation: risperidone, olanzapine, quetiapine, aripirazole. Following consent, participants will be observed for 4 weeks to ensure stability of their symptoms. Following this, there will be baseline assessments of symptom severity, cognitive ability, functional ability and an fMRI scan. Following this, participants will be randomly assigned to receive treatment with 40 mg of atomoxetine or placebo daily during a double-blind parallel designed four week treatment period, following which the dose of atomoxetine will be increased to 40 mg twice day (or matching placebo) for an additional 4 weeks. The cognitive assessment battery and MRI will be repeated following 8 weeks of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects will be males and females between the ages of 18 and 65
- •In good general medical health
- •For patient subjects, a DSM-IV diagnosis of schizophrenia, any subtype
- •Currently in remission or with stable, unchanging residual symptoms
- •Receiving treatment with olanzapine, aripiprazole, risperidone, or quetiapine as their antipsychotic medication at a stable dose for a minimum of eight weeks.
- •Able to complete neurocognitive tests
- •Able to give informed consent. All subjects will be required to have at least an 8th grade reading level and/or a full-scale IQ of at least 85 as assessed by the Wide Range Achievement Test (WRAT).
排除标准
- •Recent history (within previous year) of serious suicide, homicide, or physical violence, or current suicidal or homicidal thoughts
- •Any axis I DSM-IV diagnosis in addition to schizophrenia or schizoaffective disorder except substance abuse in remission
- •History of severe head trauma, neurological disorder, or medical illness which may contribute to the subjects' psychiatric symptoms or cognitive impairment
- •Medical illness which requires taking any medication that has CNS activity which is known to impair cognition.
- •Untreated or unstable hypertension.
- •Coronary artery disease.
- •Receiving concomitant anticholinergic drugs, antidepressants or mood stabilizers. If patient subjects are receiving benzodiazepines, they must be short or intermediate acting (e.g. alprazolam, lorazepam) and must be held 48 hours prior to cognitive testing
- •Unable to give informed consent
- •History of developmental disorder or less than an eighth
研究组 & 干预措施
Atomoxetine
Atomoxetine 40 mg compounded into capsules.
干预措施: Atomoxetine (Drug)
Placebo
Inactive matching compounding of placebo capsules
干预措施: Atomoxetine (Drug)
结局指标
主要结局
Composite score on the Brief Assessment of Cognition in Schizophrenia
时间窗: 8 weeks
Cognitive performance as measured by the BACS
次要结局
- Brain activation measured by functional magnetic resonance imaging(8 weeks)
研究者
Joseph Friedman
Principal Investigator
Research Foundation for Mental Hygiene, Inc.